Literature DB >> 10536304

In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying multiple copies of a viral CD8(+) T-cell epitope.

P Sebo1, Z Moukrim, M Kalhous, N Schaft, G Dadaglio, V Sheshko, C Fayolle, C Leclerc.   

Abstract

Bordetella pertussis adenylate cyclase toxin (ACT) is one of the few known protein toxins penetrating directly into the cytosol of target cells across their cytoplasmic membrane without the need for endocytosis. This capacity of ACT was recently exploited for in vivo delivery of single viral CD8(+) T-epitopes into MHC class I-presenting cells and induction of protective antiviral cytotoxic T-cell (CTL) responses. Here, we have explored the potential of the cell-invasive adenylate cyclase domain of the toxin to deliver larger antigens by evaluating the epitope-specific CTL responses induced by constructs bearing one to four copies of the CD8(+) T-epitope from the nucleoprotein of the lymphocytic choriomeningitis virus. The increase in the number of copies of the epitope was accompanied by a moderate decrease of the specific cell invasiveness of the ACT protein and did not lead to further enhancement of the level of induced epitope-specific CTL cells in mice, as compared to ACT with a single copy of the epitope. These results demonstrate the capacity of ACT to deliver larger heterologous antigens comprising several epitopes for antigenic presentation in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536304     DOI: 10.1111/j.1574-695X.1999.tb01385.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  6 in total

1.  Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis.

Authors:  G Dadaglio; Z Moukrim; R Lo-Man; V Sheshko; P Sebo; C Leclerc
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Delivery of a MalE CD4(+)-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase.

Authors:  Jiina Loucká; Géraldine Schlecht; Jana Vodolánová; Claude Leclerc; Peter Sebo
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.

Authors:  C Fayolle; A Osickova; R Osicka; T Henry; M J Rojas; M F Saron; P Sebo; C Leclerc
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 4.  General and molecular microbiology and microbial genetics in the IM CAS.

Authors:  Jan Nešvera
Journal:  J Ind Microbiol Biotechnol       Date:  2010-11-18       Impact factor: 3.346

5.  Recognition of mycobacterial antigens delivered by genetically detoxified Bordetella pertussis adenylate cyclase by T cells from cattle with bovine tuberculosis.

Authors:  H Martin Vordermeier; Marcela Simsova; Katalin A Wilkinson; Robert J Wilkinson; R Glyn Hewinson; Peter Sebo; Claude Leclerc
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria.

Authors:  Susanne Tartz; Jana Kamanova; Marcela Simsova; Peter Sebo; Stefanie Bolte; Volker Heussler; Bernhard Fleischer; Thomas Jacobs
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.